FactEvidence 1
public offering size$45 million
No public evidence summary is available.
BioPharma Dive · 2026-10-09 18:59
View evidence
- MediaBioPharma Dive2026-10-09 18:59View source
Company
Retension Pharmaceuticals, Inc.
Description
- Headquarters
- US
Structure of Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc.
Company
4 connections
UpstreamSupply and dependency
Relationship began
Retension Pharmaceuticals, Inc.Company · 4 connections
Layer 1UpstreamSupply and dependency4
Relations
Arrows show the direction of the relationship. Filter to focus on a business area.
- Leerink Partnersserves →Retension Pharmaceuticals, Inc.Company · Leerink PartnersEvidence 1Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
View source
- Guggenheim Securitiesserves →Retension Pharmaceuticals, Inc.Company · Guggenheim SecuritiesEvidence 1Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
View source
- Oppenheimer & Co.serves →Retension Pharmaceuticals, Inc.Company · Oppenheimer & Co.Evidence 1Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering.
View source
- Titan Partnersserves →Retension Pharmaceuticals, Inc.Company · Titan PartnersEvidence 1Fact90%
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
Titan Partners is acting as lead manager for the offering.
View source
Showing 1 to 4 of 4
Claims
Read the assertion alongside its sources. Expand a row to inspect the evidence.
FactEvidence 1
initial public offering price$12.00 per share
at an initial public offering price of $12.00 per share
GlobeNewswire public company news · 2026-10-09 09:35
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
at an initial public offering price of $12.00 per share
View source
FactEvidence 1
expected gross proceeds$45.0 million
The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million.
GlobeNewswire public company news · 2026-10-09 09:35
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million.
View source
FactEvidence 1
underwriters option term30-day
Retension has granted the underwriters a 30-day option
GlobeNewswire public company news · 2026-10-09 09:35
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
Retension has granted the underwriters a 30-day option
View source
FactEvidence 1
additional shares available under underwriters option562,500 shares
option to purchase up to an additional 562,500 shares of its common stock
GlobeNewswire public company news · 2026-10-09 09:35
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
option to purchase up to an additional 562,500 shares of its common stock
View source
FactEvidence 1
initial public offering shares3,750,000 shares
pricing of its upsized initial public offering of 3,750,000 shares of its common stock
GlobeNewswire public company news · 2026-10-09 09:35
View evidence
- CompanyGlobeNewswire public company news2026-10-09 09:35
pricing of its upsized initial public offering of 3,750,000 shares of its common stock
View source
Showing 1 to 6 of 10
Market and valuation
Valuation data is available on Pro and Research.
Included in ProNot available: Company signals · Financials · Filings · Guidance